Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Public ClinicalTrials.gov record NCT00124566. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Study identification
- NCT ID
- NCT00124566
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Eisai Inc.
- Industry
- Enrollment
- 135 participants
Conditions and interventions
Conditions
Interventions
- Irofulven Drug
- Prednisone Drug
- Mitoxantrone Drug
- Capecitabine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2004
- Primary completion
- Dec 31, 2005
- Completion
- Nov 30, 2009
- Last update posted
- Jan 17, 2016
2004 – 2009
United States locations
- U.S. sites
- 29
- U.S. states
- 15
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Hot Springs | Arkansas | — | — |
| Not listed | Jonesboro | Arkansas | — | — |
| Not listed | Greenbrae | California | — | — |
| Not listed | Colorado Springs | Colorado | — | — |
| Not listed | Bonita Springs | Florida | — | — |
| Not listed | Bradenton | Florida | — | — |
| Not listed | Cape Coral | Florida | — | — |
| Not listed | Fort Meyers | Florida | — | — |
| Not listed | Naples | Florida | — | — |
| Not listed | Port Charlotte | Florida | — | — |
| Not listed | Sarasota | Florida | — | — |
| Not listed | Venice | Florida | — | — |
| Not listed | Atlanta | Georgia | — | — |
| Not listed | Augusta | Georgia | — | — |
| Not listed | Macon | Georgia | — | — |
| Not listed | Marietta | Georgia | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Minneapolis | Minnesota | — | — |
| Not listed | Billings | Montana | — | — |
| Not listed | Albany | New York | — | — |
| Not listed | East Setauket | New York | — | — |
| Not listed | Kettering | Ohio | — | — |
| Not listed | Greenville | South Carolina | — | — |
| Not listed | Nashville | Tennessee | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Fort Worth | Texas | — | — |
| Not listed | Tyler | Texas | — | — |
| Not listed | Spokane | Washington | — | — |
| Not listed | Marshfield | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00124566, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 17, 2016 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00124566 live on ClinicalTrials.gov.